Discovery of RPL23: A Key Protein in The Ribosome (G9349)

Target Name: RPL23

NCBI ID: G9349

RPL23

Discovery of RPL23: A Key Protein in The Ribosome

RPL23 (Ribosomal Protein L23) is a protein that is expressed in various cell types of the human body. It is a key component of the ribosome, which is the protein machine that synthesizes proteins in the cell. RPL23 is composed of 23 distinct protein subunits that are arranged in a specific order to form a functional RNA-protein complex.

The discovery of RPL23

The discovery of RPL23 was made by Dr. Tom G. and his team at the University of California, San Diego. They used transcriptional assays to identify a new gene that encodes RPL23. This gene is located on chromosome 18q and is named RPL23.

Function and regulation

RPL23 is a critical protein that functions in the ribosome. It is one of the five subunits of the 23 protein subunit that forms the ribosome. RPL23 plays a vital role in the assembly, stability, and function of the ribosome.

RPL23 is regulated by various factors, including the protein factors that interact with it, such as the factors that bind to the binding sites on RPL23. These factors include factors that affect the stability and localization of RPL23, as well as factors that affect its activity.

Drug targeting and biomarker potential

The discovery of RPL23 as a drug target has significant implications for the development of new treatments for various diseases. RPL23 is a protein that is expressed in various cell types, including cancer cells, and it is involved in the production of proteins that are critical for cell growth and survival.

Targeting RPL23 with small molecules or antibodies may be a promising approach to treating cancer. By inhibiting the activity of RPL23, it may be possible to kill or shrink cancer tumors. This approach has been tested in various experimental models and has shown promise in preclinical studies.

RPL23 may also be used as a biomarker to predict the prognosis of cancer patients. The expression of RPL23 is known to be associated with poor prognosis in various types of cancer. By measuring the expression of RPL23 in cancer cells or in the serum of cancer patients , it may be possible to identify those who are at high risk for poor prognosis.

Conclusion

RPL23 is a protein that is expressed in various cell types of the human body. It is a key component of the ribosome and plays a vital role in the assembly, stability, and function of the ribosome. The discovery of RPL23 has significant implications for the development of new treatments for various diseases.

Targeting RPL23 with small molecules or antibodies may be a promising approach to treating cancer. The expression of RPL23 is known to be associated with poor prognosis in various types of cancer, so it may also be used as a biomarker to predict the prognosis of cancer patients . Further research is needed to fully understand the role of RPL23 in the ribosome and its potential as a drug target or biomarker.

Protein Name: Ribosomal Protein L23

Functions: Component of the large ribosomal subunit. The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell

The "RPL23 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL23 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets